Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37983945)

  • 1. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
    Morel M; Long W
    Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
    Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
    J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 13. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
    J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of insulin receptor substrates 1 and 2 suppresses
    Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
    Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
    Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW
    Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
    Drosten M; Barbacid M
    Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.